Neurocrine reports progress for CAH drug as Voyager partnership shifts

16 May 2025

Neurocrine Biosciences (Nasdaq: NBIX), the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help children and adults with classic congenital adrenal hyperplasia (CAH) achieve better hormone balance and reduce steroid use. The findings were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando.

In the Phase III studies, 90% of pediatric patients taking Crenessity hit at least one target for lowering androgen or steroid levels, compared to just 21% on placebo.

For adults, the drug also improved certain reproductive hormone levels, even as patients were able to cut back on steroid doses. In both age groups, the most common side effects included headache and fatigue, with adrenal crises rare.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical